Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioural activation to mitigate the psychological impacts of COVID-19 restrictions on older people in England and Wales (BASIL+): a pragmatic randomised controlled trial.

The lancet. Healthy longevity·2024
Same author

Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.

Open forum infectious diseases·2023
Same author

Harnessing synthetic biology for advancing RNA therapeutics and vaccine design.

NPJ systems biology and applications·2023
Same author

Experiences of emotional eating in an Acceptance and Commitment Therapy based weight management intervention (SWiM): A qualitative study.

Appetite·2023
Same author

Clinical consequences of weight gain during treatment for HIV infection.

Current opinion in HIV and AIDS·2023
Same author

Intersections between HIV and obesity in emerging economies.

Current opinion in HIV and AIDS·2023
Same journal

Implications of HIV persistence and pathogenesis in microglia.

Current opinion in HIV and AIDS·2026
Same journal

Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.

Current opinion in HIV and AIDS·2026
Same journal

Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.

Current opinion in HIV and AIDS·2026
Same journal

Nonhuman primate models of HIV reveal reservoir dynamics and promising interventions.

Current opinion in HIV and AIDS·2026
Same journal

Impact of sex differences in adult and paediatric HIV-1 cure.

Current opinion in HIV and AIDS·2026
Same journal

BACH2 effector-to-memory switch promotes HIV persistence and CAR-T efficacy.

Current opinion in HIV and AIDS·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Optimizing HIV treatment.

Andrew Hill1

  • 1Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. microhaart@aol.com

Current Opinion in HIV and AIDS
|November 13, 2012
PubMed
Summary
This summary is machine-generated.

Optimizing antiretroviral doses can significantly reduce HIV treatment costs. Lowering efavirenz doses and switching to dolutegravir could save nearly $1 billion annually, improving access to HIV care.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Experiment Videos

Last Updated: May 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Area of Science:

  • Infectious Diseases
  • Pharmacoeconomics
  • Public Health

Background:

  • Millions eligible for antiretroviral therapy (ART) are not receiving it.
  • An additional 19 million people will require ART as HIV progresses.
  • The Global Financial Crisis has limited funding for Universal Access to HIV treatment.

Purpose of the Study:

  • To evaluate the efficacy of lower antiretroviral doses.
  • To assess the potential cost savings and safety improvements from dose optimization.
  • To present current costs of key antiretrovirals.

Main Methods:

  • Review of ongoing randomized trials assessing lower antiretroviral doses.
  • Analysis of clinical trials for efavirenz, atazanavir, ritonavir, and stavudine.
  • Presentation of cost data for various antiretrovirals.

Main Results:

  • Three large randomized trials are investigating lower antiretroviral doses.
  • Successful dose optimization could reduce antiretroviral costs and enhance safety.
  • Specific cost reductions are projected for tenofovir (TDF)/3TC/efavirenz and dolutegravir regimens.

Conclusions:

  • Optimized antiretroviral dosing can substantially decrease the cost of Universal Access to HIV treatment.
  • Dose optimization of efavirenz to 400mg once daily could save US$192 million annually.
  • Switching to dolutegravir-based regimens could save US$801 million annually, totaling US$993 million in combined savings.